Altered conjugate formation and altered apoptosis of multidrug-resistant human leukemia cell line affects susceptibility to killing by activated natural killer (NK) cells

International Journal of Cancer

Volumn 108, Issue 1, 2004, Pages 78-85

  Treichel, Robin S ^a   Bunuan, Michael ^a   Hahn, Nancy ^a   Wee, Kathleen ^a  

^a OBERLIN COLLEGE   (United States)

Author keywords

Apoptosis; Immunotherapy; Multidrug resistance (MDR); Natural killer cells; P glycoprotein

Indexed keywords

CHROMIUM 51; CYTOTOXIC FACTOR; DNA FRAGMENT; DOXORUBICIN; GLYCOPROTEIN P; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ANIMAL CELL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; BURKITT LYMPHOMA; CANCER CELL; CELL ACTIVATION; CELL KILLING; CHRONIC MYELOID LEUKEMIA; CONJUGATION; CORRELATION ANALYSIS; FIBROSARCOMA; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MOUSE; MULTIDRUG RESISTANCE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN SECRETION;

APOPTOSIS; CYTOTOXICITY, IMMUNOLOGIC; DRUG RESISTANCE, MULTIPLE; HUMANS; K562 CELLS; KILLER CELLS, LYMPHOKINE-ACTIVATED; LEUKEMIA; LEUKEMIA, LYMPHOCYTIC, ACUTE; PHENOTYPE; TUMOR CELLS, CULTURED;

EID: 0345256397     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11555     Document Type: Article

References (21)

1. Van den Heuvel-Eibrink MM, Sonneveld P, Pieters R. The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia. Intl J Clin Pharm Ther 2000;38:94-110.
2. Pieters R, Klumper E, Kaspers GJ, Veerman AJ. Everything you always wanted to know about cellular drug resistance in childhood acute lymphoblastic leukemia. Crit Rev Oncol Hematol 1997;25:11-26.
3. Herberman RB. Cancer immunotherapy with natural killer cells. Semin Oncol 2002;3:27-30.
4. Ruggeri, L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardil A. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097-100.
5. Lanier LL. Turning on natural killer cells. J Exp Med 2000;191:1259-62.
6. Karawajew L, Wuchter C, Rupper V, Drexler H, Gruss HJ, Dorken B, Ludwig WD. Differential CD95 expression and function in T and B lineage acute lymphoblastic leukemia cells. Leukemia 1997;11:1245-52.
7. Malorni W, Rainaldi G, Tritarelli E, Rivabene R, Cianfriglia M, Lehnert M, Donelli G, Peschele C, Testa U. Tumor Necrosis Factor alpha is a powerful apoptotic inducer in lymphoid leukemic cells expressing the p-170 glycoprotein. Int J Cancer 1996;67:238-47.
8. Savas B, Cole SP, Akoglu TF, Pross HF. P-glycoprotein-mediated multidrug resistance and cytotoxic effector cells. Nat Immun 1992; 11:177-92.
9. Gambacorti-Passerini C, Rivoltini L, Supino R, Rodolfo M, Radrizzani M, Fossati G, Parmiani G. Susceptibility of chemoresistant murine and human tumor cells to lysis by interleukin 2-activated lymphocytes. Cancer Res 1988;48:2372-6.
10. Treichel RS, Olken S. The relationship between multidrug resistance and resistance to natural killer cells and lymphokine-activated killer cell lysis in human leukemic cell lines. Int J Cancer 1992;50:305-10.
11. Kimmig A, Gekeler V, Neumann M, Frese G, Handgretinger R, Kardos G, Diddens H., Niethammer D. Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells. Cancer Res 1990;50:6793-9.
12. Yanovich S, Hall RE, Weinert C. Resistance to natural killer cell-mediated cytolysis by a pleiotropic drug-resistant human erythroleukemia (K562-R) cell line. Cancer Res 1986;46:4511-5.
13. Woods G, Lund LA, Naid M, Ling V, Ochi A. Resistance of multidrug-resistant lines to natural killer-like cell-mediated cytotoxicity. FASEB J 1988;2:2791-6.
14. +/H+ exchanger activation in target cell-adherent human NK cells. J Immunol 1993;150:4766-76.
15. Treichel RS. Autologous bone marrow transplantation for leukemia: monoclonal antibody-mediated purging of multidrug-resistant leukemia. Leuk Res 1993;17:491-9.
16. Shresta S, Pham CTN, Thomas DA, Graubert TA, Ley TJ. How do cytotoxic lymphocytes kill their targets? Curr Opin Immunol 1998; 10:581-7.
17. Burshtyn DN, Shin J, Stebbins C, Long EO. Adhesion of target cells is disrupted by the killer cell inhibitory receptor. Curr Biol 2000;10: 777-80.
18. Johnstone RW, Tainton KM, Ruefli AA, Froelich CJ, Cerruti L, Jane SM, Smyth MJ. P-glycoprotein does not protect cells against cytolysis induced by pore-forming proteins. J Biol Chem 2001;276:16667-73.
19. Johnstone RW, Cretney E, Smyth MJ. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent death. Blood 1999;93:1075-85.
20. Robinson LJ, Roberts WK, Ling TT, Lamming D, Sternberg SS, Roepe PD. Human MDR 1 protein overexpression delays the apoptotic cascade in Chinese hamster ovary fibroblasts. Biochem 1997;36: 11169-78.
21. Campone M, Vavasseur F, Le Cabellec MT, Meflah K, Vallette FM, Oliver L. Induction of chemoresistance in HL-60 cells concomitantly causes a resistance to apoptosis and the synthesis of P-glycoprotein. Leukemia 2001;15:1377-87.